| Title |
Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome
|
|---|---|
| Published in |
Alzheimer's Research & Therapy, April 2018
|
| DOI | 10.1186/s13195-018-0367-x |
| Pubmed ID | |
| Authors |
Andre Strydom, Amanda Heslegrave, Carla M. Startin, Kin Y. Mok, John Hardy, Jurgen Groet, Dean Nizetic, Henrik Zetterberg, The LonDownS Consortium |
| Abstract |
Down syndrome (DS) may be considered a genetic form of Alzheimer's disease (AD) due to universal development of AD neuropathology, but diagnosis and treatment trials are hampered by a lack of reliable blood biomarkers. A potential biomarker is neurofilament light (NF-L), due to its association with axonal damage in neurodegenerative conditions. We measured blood NF-L concentrations in 100 adults with DS using Simoa NF-light® assays, and we examined relationships with age as well as cross-sectional and longitudinal dementia diagnosis. NF-L concentrations increased with age (Spearman's rho = 0.789, p < 0.001), with a steep increase after age 40, and they were predictive of dementia status (p = 0.022 adjusting for age, sex, and APOE4), but they showed no relationship with long-standing epilepsy or premorbid ability. Baseline NF-L concentrations were associated with longitudinal dementia status. NF-L is a biomarker for neurodegeneration in DS with potential for use in future clinical trials to prevent or delay dementia. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 33% |
| United States | 3 | 33% |
| Finland | 1 | 11% |
| Cyprus | 1 | 11% |
| Unknown | 1 | 11% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 56% |
| Practitioners (doctors, other healthcare professionals) | 2 | 22% |
| Scientists | 2 | 22% |
Mendeley readers
The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 97 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 18% |
| Student > Ph. D. Student | 15 | 15% |
| Student > Master | 10 | 10% |
| Student > Bachelor | 10 | 10% |
| Other | 7 | 7% |
| Other | 14 | 14% |
| Unknown | 24 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 26 | 27% |
| Medicine and Dentistry | 11 | 11% |
| Biochemistry, Genetics and Molecular Biology | 9 | 9% |
| Psychology | 8 | 8% |
| Agricultural and Biological Sciences | 4 | 4% |
| Other | 10 | 10% |
| Unknown | 29 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 February 2019.
All research outputs
#1,670,219
of 23,041,514 outputs
Outputs from Alzheimer's Research & Therapy
#292
of 1,246 outputs
Outputs of similar age
#38,946
of 329,244 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#5
of 25 outputs
Altmetric has tracked 23,041,514 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,246 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.9. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,244 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.